Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

10 May 2016 - 16 May 2016
11 May 2016 - 13 May 2016

Congress Presentation Highlights the 50 Most Innovative Technologies in 2013

By BiotechDaily International staff writers
Posted on 21 May 2013
Print article
Up to 85% of technologies developed globally never reach the business setting. Business personnel and investors need to closely assess the potential of a specific technology platform to determine the real market potential it has and to assess the risk-reward fundamentals.

Fifty of the most innovative technologies worldwide were recently presented at GIL (Growth, Innovation, Leadership) 013: Europe—The Global Community of Growth, Innovation, and Leadership annual congress, held in London (UK), presented by Frost & Sullivan (Palo Alto, CA, USA), an international growth consultancy firm. During the congress on May 14, 2013, Frost & Sullivan’s practice director for technical insights, Europe, Ankit A. Shukla, presented a unique research platform called “TechVision 2020: A Systematic Innovation Serendipity Engine.” This research revealed the 50 most innovative technologies set to considerably transform industries, strategies, and businesses in 2013.

The chosen technologies that were discussed at the congress extended across nine sectors--health and wellness, medical devices and imaging technology, advanced manufacturing and automation, sensors and control, materials and coatings, clean and green environment, information and communication technology, microelectronics, sustainable energy--and represent the majority of R&D and innovation activity today.

“Apart from identifying the top 50 technologies for 2013, our global technology team has identified various convergence opportunities enabled by a combination of the technologies. We believe these identified opportunities represent exciting times ahead for the multitude of industries and markets they will impact,” remarked Mr. Shukla.

Convergence opportunities can be found across various industry segments. One of the most thought-provoking ones is self-healing organs. Several years ago, this was just a topic for science fiction literature and movies; now it can be accomplished by the merging of the following technologies: carbon fibers, polymer chameleons, three-dimensional (3D) printing. The combination of these technologies will cut the amount of tissue rejection and also the presence of polymer chameleons that can be modified to self-heal in case of injuries and wear and tear.

Another example is interactive augmented reality (AR) that can be enabled for predictive remote patient monitoring. Capabilities converging in this case are information and communications technology (ICT) technologies (augmented reality; cloud computing; Big Data analytics; data visualization) and sensors (ubiquitous wireless sensor network; nanosensors and CBRNE [chemical, biologic, radiologic, nuclear, and high-yield explosives] sensors). The combination of selected ICT and sensor technologies could provide personalized disease management tools that help better manage predicted symptoms, chronic illness, and episodic acute disorders.

TechVision 2020 showcased each selected technology, carefully evaluating the potential of a given technology platform to understand the true market opportunities, while evaluating the risk-reward fundamentals. It appraises technology maturity and adoption ratings, possible year of impact and patent landscape, examines private and government funding trends, and examines future technology and application roadmaps. Furthermore, more interestingly, the output evaluated future convergence opportunities as well as the next leaps in innovation that will have a lasting impact on industries and markets.

“In order not to remain in the ‘Valley of Death,’ investors have to understand the potential of their technology and the true value it can bring. Innovative products are different; they are not in compliance with existing standards. Sometimes, revenues are not so obvious and ROI [return of investment] can take more time. The important aspect here is to educate end-users and society about the benefits innovative technology and products can bring,” summarized Mr. Shukla.

Related Links:

Frost & Sullivan
GIL 2013-Global Community of Growth, Innovation, and Leadership Congress



Print article

Channels

Genomics/Proteomics

view channel
Image: An artistic rendering of the Zika virus structure (Photo courtesy of Dr. Guntur Fibriansah, Duke-NUS Medical School).

High Resolution Structure of Zika virus Expected to Aid Vaccine Development

A team of molecular virologists used advanced cryo-electron microscopy techniques to establish a high-resolution structure for the Zika virus, a formerly neglected pathogen that has recently been associated... Read more

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.